Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Biotie

- PMLiVE

AbbVie announces acquisition of Mitokinin in deal worth over $650m

The agreement gives AbbVie access to a potential treatment for Parkinson’s disease

- PMLiVE

MJFF awards Nine Square Therapeutics $4.5m for Parkinson’s disease research

The research grant will help to identify drug candidates for the treatment of the disease

- PMLiVE

New blood test could one day be used to diagnose Parkinson’s disease

The discovery could potentially lead to the development of a definitive diagnostic test

- PMLiVE

International survey reveals varying effects of oral medicines for Parkinson’s

More than 65% of respondents reported variations in the effects of taking oral medications

Bayer symbol

Bayer and BlueRock announce positive results from Parkinson’s cell therapy trial

Phase 1 results suggest the stem cell-based treatment improves symptoms of the condition

- PMLiVE

Study reveals gut conditions could be early sign of Parkinson’s disease

Constipation, dysphagia and IBS could be potential biomarkers of the condition

- PMLiVE

Study shows AI scans could detect Parkinson’s years before clinical presentation

OCT scans could be used by the NHS for the diagnosis of neurodegenerative diseases

- PMLiVE

FDA declines to approve Amneal Pharmaceuticals’ Parkinson’s disease treatment

The regulator said the safety for one of the drug's ingredients had not been adequately established

Bayer symbol

Bayer and BlueRock announce positive early-stage results for Parkinson’s cell therapy

The progressive neurological disorder affects around ten million people worldwide

- PMLiVE

Study unveils ‘breakthrough biomarker’ for Parkinson’s disease

Researchers say they can measure a protein to determine the likelihood that someone will develop the disease

- PMLiVE

AbbVie’s Parkinson’s disease therapy application rejected by FDA

The regulator has requested more information on the pump used to administer ABBV-95

- PMLiVE

Eisai and Washington University to develop neurodegenerative disease therapies

Alzheimer’s will be a central focus for the new drug discovery collaboration

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links